Print this article Caitlyn Jenner poses at the Glamour Women of the Year Awards in Los Angeles, Calif., November 14, 2016.
(Mario Anzuoni/Reuters)
Much has been made of Caitlyn Jenner opining that biological males who are transgender should not be allowed to compete in girl’s sports because it “isn’t fair.”
Under pressure from LGBT and other critics, Jenner softened the opinion in an interview, stating on Fox News that if the athlete “transitioned” early, it would be okay for trans girls to compete athletically against biologically born females. From the National Review report (my emphasis):
“What I would do as governor, I would put together a commission,” Jenner said. “Trans women compete in the Olympics, they compete in the NCAA, but when it gets down to the high school level, there’s no guide rules, there’s no rules and regulations how they can.”
Anatomy Of A Hunger Strike: Why Is It Done And What Does It Do To The Human Body? rferl.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rferl.org Daily Mail and Mail on Sunday newspapers.
(Sergey Tinyakov/Getty Images)
The actual science is beginning to overcome transgender ideology. First, the U.K.’s National Institute for Health and Care Excellence basically the NHS’s decision-maker for what to cover determined that there was “very low” evidence of benefit to allow children with gender dysphoria to have their natural puberty blocked which is an “off label” use of those drugs, by the way.
Now, Karolinska Hospital, a major health institution in Sweden, is stopping their use. First, there is little scientific to support such interventions. From the hospital’s official statement:
In December 2019, the SBU (Swedish Agency for Health Technology Assessment and Assessment of Social Services) published an overview of the knowledge base which showed a lack of evidence for both the long-term consequences of the treatments, and the reasons for the large influx of patients in recent years.
How AstraZeneca Blood Clot Risk Compares to Contraceptive Pill, Smoking, Long-Haul Flights
On 4/8/21 at 8:40 AM EDT
On Wednesday, the European Medicines Agency (EMA) stated that blood clots with low blood platelets should be listed as very rare side effects of the Oxford-AstraZeneca (AZ) COVID vaccine.
It came to its conclusion based on a review of 86 blood clotting cases reported in the EU drug safety database, 18 of which were fatal. Most of these cases were reported from the EU as well as the U.K., where roughly 25 million people have received the jab. The EMA added the benefits of the vaccine still outweigh the risks.
First published on
While attention focused on iRhythm Technologies after Medicare rates for long-term cardiac monitoring were slashed in January, the fallout is now extending to other players and the future of the much-hyped market is being questioned.
Novitas Solutions, which sets regional Medicare rates as a Medicare Administrative Contractor, is working with iRhythm and rivals about possibly changing the published rates. However, there is no timetable for when or if the rates will change, leaving Wall Street and industry in a holding pattern.
Baird Equity Research analyst Mike Polark said that the reimbursement uncertainty makes any long-term growth expectation for iRhythm and the overall cardiac wearables market difficult.